Page 7 - உலகளாவிய இரத்தம் சிகிச்சை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global Blood Therapeutics, Inc.: Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patient (voxelotor) Tablets Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes Oxbryta blocks polymerization and the resultant sickling and destruction of red blood cells, which are primary pathologies faced by every single person living with SCD. Through addressing hemolytic anemia and improving oxygen delivery throughout the body, GBT believes that Oxbryta has the potential to modify the course of SCD. On Nov. 25, 2019, Oxbryta received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of SCD in adults and children 12 years of age and

United statesCity ofUnited kingdomSteven immergutCourtney robertsRjo howardKing college londonCenters for diseaseEuropean commissionDrug administrationGlobal blood therapeutics incExchange commissionSecurities exchangeEuropean medicines agencyNational heartBlood institute